- Tengion Inc. Provides Business Update and Reports First Quarter 2013 Financial Results
- Tengion Inc. Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
- Tengion Inc. Provides Business Update and Reports Fourth Quarter and Full Year 2012 Financial Results
- Tengion Inc. to Present at 25th Annual ROTH Conference
- Tengion Inc. to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference
- Tengion Inc. Announces Clinical Progress for Neo-Urinary Conduit™ Phase 1 Trial and Regulatory Advance for Neo-Kidney Augment™
- Tengion Inc. Announces Change to Board of Directors
- Tengion Inc. Provides Business Update and Reports Third Quarter 2012 Financial Results
- Form 10-Q TENGION INC For: Jun 30
- Tengion Announces Listing Transfer From NASDAQ Global Market® To NASDAQ Capital Market®
- Tengion Announces Significant Advances in Neo-Urinary Conduit™ and Neo-Kidney Augment™ Programs
- Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
- new CEO - Tengion Appoints John L. Miclot President and Chief Executive Officer
- in FREE FALL
- Tengion centering R&D in Winston-Salem
- Tengion Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
- Tengion Appoints New BoD
- How is Tengion Inc still on the NASDAQ?
- Tengion to Present at Rodman & Renshaw
- Dr. Atala Compensation?
- Tengion and Dr. Anthony Atala from Wake Forest